Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey

por Pinkerton, JoAnn V., Constantine, Ginger D.
Publicado 2016

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program

por Constantine, Ginger D., Goldstein, Steven R., Archer, David F.
Publicado 2015

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors

por Constantine, Ginger D., Kessler, Grant, Graham, Shelli, Goldstein, Steven R.
Publicado 2019

Systemic estradiol levels with low-dose vaginal estrogens

por Santen, Richard J., Mirkin, Sebastian, Bernick, Brian, Constantine, Ginger D.
Publicado 2019

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

por Constantine, Ginger D., Archer, David F., Graham, Shelli, Bernick, Brian A., Mirkin, Sebastian
Publicado 2016

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial

por Kaunitz, Andrew M., Bitner, Diana, Constantine, Ginger D., Bernick, Brian, Graham, Shelli, Mirkin, Sebastian
Publicado 2020

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence

por Archer, David F., Carr, Bruce R., Pinkerton, JoAnn V., Taylor, Hugh S., Constantine, Ginger D.
Publicado 2015

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone

por Mirkin, Sebastian, Graham, Shelli, Revicki, Dennis A., Bender, Randall H., Bernick, Brian, Constantine, Ginger D.
Publicado 2019

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review

por Constantine, Ginger D., Graham, Shelli, Lapane, Kate, Ohleth, Kathleen, Bernick, Brian, Liu, James, Mirkin, Sebastian
Publicado 2019

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries

por Constantine, Ginger D, Graham, Shelli, Clerinx, Cathy, Bernick, Brian A, Krassan, Mitchell, Mirkin, Sebastian, Currie, Heather
Publicado 2016

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmen...

por Constantine, Ginger D., Bouchard, Celine, Pickar, James H., Archer, David F., Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Publicado 2017

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial

por Simon, James A., Archer, David F., Kagan, Risa, Bernick, Brian, Graham, Shelli, Constantine, Ginger D., Mirkin, Sebastian
Publicado 2017

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms

por Constantine, Ginger D., Revicki, Dennis A., Kagan, Risa, Simon, James A., Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Publicado 2019

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR

por Kingsberg, Sheryl A., Kroll, Robin, Goldstein, Irwin, Kushner, Harvey, Bernick, Brian, Graham, Shelli, Mirkin, Sebastian, Constantine, Ginger D.
Publicado 2017

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol

por Archer, David F., Constantine, Ginger D., Simon, James A., Kushner, Harvey, Mayer, Philip, Bernick, Brian, Graham, Shelli, Mirkin, Sebastian
Publicado 2017

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estr...

por Lobo, Rogerio A., Liu, James, Stanczyk, Frank Z., Constantine, Ginger D., Pickar, James H., Shadiack, Annette M., Bernick, Brian, Mirkin, Sebastian
Publicado 2019

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial

por Constantine, Ginger D., Simon, James A., Kaunitz, Andrew M., Pickar, James H., Revicki, Dennis A., Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Publicado 2020

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atroph...

por Constantine, Ginger D., Simon, James A., Pickar, James H., Archer, David F., Kushner, Harvey, Bernick, Brian, Gasper, Gina, Graham, Shelli, Mirkin, Sebastian
Publicado 2017

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

por Christiansen, Claus, Chesnut, Charles H, Adachi, Jonathan D, Brown, Jacques P, Fernandes, César E, Kung, Annie WC, Palacios, Santiago, Levine, Amy B, Chines, Arkadi A, Constantine, Ginger D
Publicado 2010